Replies to post #99216 on Biotech Values

[Elroy Jetson]

I agree that "standard trial length" is indeed too short to capture many differences in drug durability to viral resistance.

This merely means that an inferior drug is identical to a superior drug over a relatively short duration. While this may provide the inferior drug a marketing advantage they would not have otherwise had, it does not change the real world inferiority of the drug.

Worse still this will create a large group of former Isentress patients who are now unnecessarily resistant to newer integrase inhibitors with higher drug resistance hurdles.
.